This business report from July 2014 is based
on the identification, description and assessment of all relevant stakeholders
in the field of botulinum neurotoxins. The report analyzes the existing product
portfolios in regulated and less regulated markets, commercial information, and
measures to maintain sales and market shares by upside indications and life
cycle management measures. The report addresses the new wave of botulinum
neurotoxin product candidates in development, such as biosimilars and
biosuperior botulinum neurotoxins.
Special emphasis is put in the report on
improvements by pharmaceutical technologies, such as liquid protein formulations
and transdermal drug delivery technologies. The significance of recombinant DNA
technology is discussed regarding botulinum neurotoxin engineering,
modification and manufacturing. Chances and challenges for the stakeholders in
the botulinum neurotoxin market are evaluated.
The market for botulinum neurotoxin products
has significantly grown over the last years, due to new medical indications
developed and due to more cosmetic procedures performed with botulinum
neurotoxins in ageing societies in which physical appearance is highly valued.
Although the botulinum neurotoxin market commercially is dominated by only one
company, existing competitors, new players and technologies are setting the
ground for biosuperiors as well as for biosimilars. As biosimilar botulinum
toxins will put the price of first generation products under pressure, only
innovation can justify higher prices.
Benefits
from the report:
- Identify established and emerging players in the field
- Find out which enabling technologies are attractive for the next generation
- Understanding the driving forces for the future of the botulinum neurotoxin market
- Learn the key success factors in marketing new botulinum neurotoxin products
- Recognize the challenges acting on established stakeholders
- Learn which technologies and product candidates are attractive for partnering
Spanning over 169 pages,“Botulinum Neurotoxins: A comparative industry analysis of
products, pipelines, technologies and stakeholders” report
covering the Executive Summary, Overview, Botulinum Neurotoxin Products
Available in Regulated Markets, BoNTs in Less Regulated Markets, Biosimilar
Botulinum Neurotoxin, Biosuperior, Next Generation Botulinum Neurotoxins,
Botulinum Neurotoxin Market Stakeholders and Enabling Technologies, Botulinum
Neurotoxin Company Profiles, References, Competitor Analysis Tables. The report
covered few companies are - Allergan, Alphaeon, Anterios, CROMA Pharma,
Daewoong Pharmaceutical Co, Eisai, Escape Therapeutics, Galderma, Hugel, Ipsen
See
Table of contents & Purchase this publication at: - http://mrr.cm/Zs4
No comments:
Post a Comment
Note: only a member of this blog may post a comment.